

Docket No. 220572US0X PCT

10/069961  
JC19 Rec'd P&T/PTO 08 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2

IN RE APPLICATION OF: Michele MOCK

SERIAL NO: New US PCT application based on PCT/FR00/02494

GAU:

FILED: Herewith

EXAMINER:

FOR: ACELLULAR IMMUNOGENIC COMPOSITIONS AND ACELLULAR VACCINE COMPOSITIONS AGAINST BACILLUS ANTHRACIS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

*Surinder Sachar*

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/01)

Docket No. 220572US0X PCT

10/069961  
JG19 Rec'd PCT/PTO 08 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michele MOCK

SERIAL NO: New US PCT application based on PCT/FR00/02494

GAU:

FILED: Herewith

EXAMINER:

FOR: ACELLULAR IMMUNOGENIC COMPOSITIONS AND ACELLULAR VACCINE COMPOSITIONS AGAINST BACILLUS ANTHRACIS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.




Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/01)

10/069961

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.  220572US0X PCT		SERIAL NO. New US PCT application based on PCT/FR00/02494	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT  Michele MOCK			
				FILING DATE  Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	2 115 433	07/20/98	RU		No	
	AP	92 19720	11/12/92	WO		No	
	AQ	0 739 981	10/30/96	EP		No	
	AR						
	AS						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AT	S.L. WELKOS et al.: "Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice" MICROBIAL PATHOGENESIS, vol. 5, no. 3, pages 127-140 1988					
	AU	P.C.B. TURNBULL: "Anthrax vaccines: past, present, and future" VACCINE, vol. 9, no. 8, pages 533-539 08/01/91					
	AV	A.V. STEPANOV et al.: "Development of novel vaccines against anthrax in man" JOURNAL OF BIOTECHNOLOGY, vol. 44, no. 1, pages 155-160 01/26/96					
	AW	V.A. ABALAKIN et al.: "Protective and other biological properties of Bacillus anthracis soluble antigen" JOURNAL OF HYGIENE, EPIDEMIOLOGY, MICROBIOLOGY, AND IMMUNOLOGY, vol. 35, no. 1, pages 83-91 1991					
	AX	V.A. ABALAKIN et al.: "Vlianie protektivnogo antigena Bacillus anthracis na formirovanie immuniteta pod deistviem sibireiazvennykh jivvykh vaktsin" ZHURNAL MIKROBIOLOGII, EPIDEMIOLOGII I IMMUNOLOGII, no. 5, pages 72-75 1990				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							